Miguel Ángel Galve
General Counsel at Cellerix SA
Profile
Miguel Ángel Galve is a professional who has worked as a Legal Director at Cellerix SA, and previously held the same position at Icron Group Holding Ltd.
and Genetrix SL.
He has an undergraduate degree from Universidad de Murcia and a graduate degree from Université Paris Dauphine-PSL.
Currently, he is working as a Legal Director at Cellerix SA.
Miguel Ángel Galve active positions
Companies | Position | Start |
---|---|---|
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | General Counsel | 24/11/2009 |
Former positions of Miguel Ángel Galve
Companies | Position | End |
---|---|---|
Icron Group Holding Ltd.
Icron Group Holding Ltd. Wireless TelecommunicationsCommunications Icron Group Holding Ltd. is the British parent company of Vectone Mobile, a Mobile Virtual Network Operator owned by the Mundio Group. The private company offers affordable international call solutions and is based in London, UK. It has subsidiaries in Poland, Ireland, and the United Kingdom. The company was founded in 1999. | General Counsel | - |
Genetrix SL
Genetrix SL BiotechnologyHealth Technology Genetrix SL develops biotechnological solutions. It is comprised of technology and biomedicine companies in order to maximize the value of the Group. The company was founded in May 20, 2003 and is headquartered in Madrid, Spain. | General Counsel | - |
Training of Miguel Ángel Galve
Université Paris Dauphine-PSL | Graduate Degree |
Universidad de Murcia | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Icron Group Holding Ltd.
Icron Group Holding Ltd. Wireless TelecommunicationsCommunications Icron Group Holding Ltd. is the British parent company of Vectone Mobile, a Mobile Virtual Network Operator owned by the Mundio Group. The private company offers affordable international call solutions and is based in London, UK. It has subsidiaries in Poland, Ireland, and the United Kingdom. The company was founded in 1999. | Communications |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Health Technology |
Genetrix SL
Genetrix SL BiotechnologyHealth Technology Genetrix SL develops biotechnological solutions. It is comprised of technology and biomedicine companies in order to maximize the value of the Group. The company was founded in May 20, 2003 and is headquartered in Madrid, Spain. | Health Technology |
- Stock Market
- Insiders
- Miguel Ángel Galve